Daratumumab, a humanized mAb that targets a specific epitope on the CD38 protein (a transmembrane glycoprotein with ectoenzymatic activity and present predominantly on the surface of plasma cells), is available for patients with newly diagnosed MM. The gene discussed is CD38; the disease is Miyoshi myopathy.